53,785 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Purchased by Wellington Management Group LLP

Wellington Management Group LLP purchased a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 53,785 shares of the company's stock, valued at approximately $1,473,000. Wellington Management Group LLP owned approximately 0.18% of Dianthus Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quest Partners LLC boosted its holdings in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after buying an additional 1,124 shares during the last quarter. SG Americas Securities LLC bought a new stake in Dianthus Therapeutics during the second quarter worth about $112,000. The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics during the second quarter worth about $236,000. Fred Alger Management LLC lifted its stake in shares of Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock worth $264,000 after buying an additional 3,316 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in Dianthus Therapeutics during the 2nd quarter worth $265,000. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Stock Down 1.0 %

Shares of NASDAQ:DNTH traded down $0.24 during trading on Thursday, hitting $23.04. The stock had a trading volume of 315,193 shares, compared to its average volume of 205,047. Dianthus Therapeutics, Inc. has a 12-month low of $7.16 and a 12-month high of $33.77. The stock has a 50-day simple moving average of $25.77 and a two-hundred day simple moving average of $26.60. The stock has a market capitalization of $681.91 million, a price-to-earnings ratio of -9.22 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $2.17 million during the quarter, compared to analysts' expectations of $1.07 million. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analysts Set New Price Targets

DNTH has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Finally, Oppenheimer boosted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $46.43.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.